Ivermectin Clinical Trial
— GALECRUSTEDOfficial title:
A Randomized Controlled Double-blind Trial Assessing the Efficacy of a 400µg/kg Ivermectin /5% Permethrin / Emollient Cream Regimen in Patients With Crusted Scabies as Compared to a 200µg/kg Ivermectin /5% Permethrin /Emollient Cream Regimen
Verified date | September 2023 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Severe forms of scabies (crusted scabies and profuse scabies) require a specific treatment. Ivermectin is a recommended treatment in common forms of scabies and represents a promising treatment in crusted scabies in case reports. However, response to ivermectin remains variable among studies, and there is no consensus on the schemes to adopt (dosages and administrations). Ivermectin at 400 µg/kg has already been used, without showing toxicity (in head lice treatment in particular). Investigators propose to demonstrate that 400µg/kg ivermectin dosage will show better efficacy than a 200µg/kg in patients with severe forms of scabies (crusted and profuse).
Status | Completed |
Enrollment | 133 |
Est. completion date | January 12, 2022 |
Est. primary completion date | January 12, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients = 18 years old, diagnosed with severe forms of scabies 1. clinical criteria : cutaneous lesions of scabies - crusted scabies: at least two sites of hyperkeratosis will define crusted scabies and/or - profuse scabies : spreading lesions with erythematous scaly eruption of the neck, face or trunk without hyperkeratosis 2. paraclinical criteria: - Positive parasitological test - and/or dermoscopic exam with signs of scabies Effective contraception for women in age of pregnancy Written consent from patient or his/her legal representant, trustworthy person or family member Affiliated to a social security scheme Exclusion Criteria: - Pregnant and/or breastfeeding women - Intolerance to ivermectin or topical treatment (permethrin 5% cream) or emollient cream - Use of anti parasitic drug (ivermectin or albendazole) within the past 7 days - Abnormal liver test results: ALT and/or AST >3N within the past 7 days (within 6 months if no hepatic history) - Participation in other biomedical drug research - Patient deprived of freedom - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule |
Country | Name | City | State |
---|---|---|---|
France | Henri Mondor Hospital | Creteil |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of a successful treatment defined by : -Two negative parasitologic and/or two dermoscopic exams | Parasitologic and/or dermoscopic exams will be perform at days 18 +/-2days and at days 21+/-2 days | Days 21+/-2 days | |
Primary | Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions | Days 28+/- 2 days | ||
Secondary | Rate of adverse effects | Days 18 +/-2 days, Days 21+/-2 days and Days 28+/-2 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04891250 -
The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19
|
Phase 4 | |
Completed |
NCT03052998 -
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
|
Phase 4 | |
Completed |
NCT04434144 -
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
|
||
Completed |
NCT03459794 -
Ivermectin and Human Immunity
|
Early Phase 1 | |
Active, not recruiting |
NCT06332872 -
Comparison Effectiveness of Oral Ivermectin , 1% Permethrin Shampoo and 4% Dimeticone Liquid Gel in the Treatment of Pediculosis Capitis Among School Children in Chachoengsao Province, Thailand
|
Phase 4 |